Positive Phase IIa results for Revolo's EoE candidate

Privately held, venture-funded biotech Revolo Biotherapeutics, previously known as Immune Regulation, today announced positive top-line data from its proof-of-concept Phase IIa clinical trial evaluating the efficacy, safety, and tolerability of the company’s immune-resetting drug, ‘1104, in adults with active eosinophilic esophagitis (EoE).

Revolo, which has headquarters in the UK and USA, noted that, despite the short duration of treatment, patients treated with ‘1104 showed a dose dependent numeric reduction from baseline in the peak esophageal intraepithelial eosinophil count compared to the placebo group.

In addition, ‘1104 treated patients showed positive results on a broad array of other biologic measures thought to be key drivers of EoE. Importantly, ‘1104 treated patients showed an increase in both Regulatory B cells (Bregs) and Regulatory T cells (Tregs) that act to suppress inflammatory immune responses. These findings have not been reported for any other mechanism in EoE.